Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. It serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.

Revenue projections:

Revenue projections for JUBLPHARMA
Revenue projections for JUBLPHARMA

With JUBLPHARMA's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 0.000000
forwardPE 23.228182
debtToEquity 43.776000
earningsGrowth -0.787000
revenueGrowth 0.098000
grossMargins 0.679410
operatingMargins 0.100750
trailingEps 28.980000
forwardEps 0.000000

Jubilant Pharmova Limited's Forward PE is positioned well, reflecting a favorable balance between stock price and earnings. The stock isn't overpriced, offering room for growth and making it a potentially rewarding investment as its value has room to rise further.
JUBLPHARMA's low earnings and revenue growth suggest that the company's profits may shrink. This trend could indicate underlying financial struggles and pose challenges for JUBLPHARMA's future profitability.
Jubilant Pharmova Limited's negative gross and operating margins indicate that the company is currently unprofitable at both the production and operational levels. This suggests significant challenges in managing costs and generating revenue, which could impact its overall financial health.

Price projections:

Price projections for JUBLPHARMA
Price projections for JUBLPHARMA

Over time, price projections for Jubilant Pharmova Limited have been gradually revised upward, reflecting increasing optimism about the company's future performance. This trend suggests analysts are growing more confident in Jubilant Pharmova Limited's ability to deliver strong results and achieve higher market value.

Insider Transactions:

Insider Transactions for JUBLPHARMA
Insider Transactions for JUBLPHARMA


Jubilant Pharmova Limited had 1 buy transactions, with market price of 1219.5999755859375.No buy transactions were carried out during the period under review.JUBLPHARMA's current price levels are experiencing more selling than buying, which may suggest further declines. If the trend persists, it could lead to a continued downward trajectory as investors lose confidence in the stock's future performance.

Recommendation changes over time:

Recommendations trend for JUBLPHARMA
Recommendations trend for JUBLPHARMA


Analysts have shown a buy bias for JUBLPHARMA, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to JUBLPHARMA, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.